鸟苷酸环化酶C激动剂治疗便秘型肠易激综合征与慢性特发性便秘的疗效与耐受性:系统评价与Meta分析
系统评价与Meta分析纳入8项利那洛肽试验和7项普卡那肽试验共10369例患者,评估两者对慢性特发性便秘(CIC)和便秘型肠易激综合征(IBS-C)的疗效与耐受性。两种药物对CIC和IBS-C均有效,但腹泻发生率高于安慰剂;Meta回归显示两药在疗效、腹泻或腹泻相关退组的比值比上无统计学显著差异。
要点
- 利那洛肽和普卡那肽对CIC和IBS-C均有效,各剂量汇总OR值均大于1且95%CI不跨1。
- 两药腹泻发生率均高于安慰剂,各剂量汇总OR值均大于1且95%CI不跨1。
- Meta回归显示两药在疗效、腹泻或腹泻相关退组的比值比上无统计学显著差异。
核心结论
- 利那洛肽和普卡那肽治疗IBS-C和CIC的疗效与耐受性相似。
- 利那洛肽与普卡那肽之间未见腹泻 odds 差异。
研究设计与样本
- 系统评价与Meta分析,检索PubMED、EMBASE、Cochrane数据库、clinicaltrials.gov、主要会议摘要、美国食品药品监督管理局(FDA)网站及药物申办方提交美国证券交易委员会的文件。
- 纳入8项利那洛肽试验(5项CIC;3项IBS-C)和7项普卡那肽试验(4项CIC;3项IBS-C),共评估10369例患者。
- 采用DerSimonian和Laird随机效应模型汇总试验结果,适当时采用精确logistic回归,并提供95%置信区间;进行Meta回归比较不同疗法结局并校正安慰剂事件率。
主要发现
- 治疗CIC的疗效:利那洛肽72 μg(OR=3.11,95%CI 1.81-5.34);利那洛肽145 μg(OR=3.25,95%CI 2.15-4.91);普卡那肽3 mg(OR=1.99,95%CI 1.57-2.51)。
- 治疗IBS-C的疗效:利那洛肽290 μg(OR=2.43,95%CI 1.48-3.98);普卡那肽3 mg(OR=1.87,95%CI 1.47-2.38);普卡那肽6 mg(OR=1.92,95%CI 1.48-2.48)。
- 治疗CIC时腹泻发生率高于安慰剂:利那洛肽72 μg(OR=3.07,95%CI 1.97-4.77);利那洛肽145 μg(OR=3.70,95%CI 2.69-5.10);普卡那肽3 mg(OR=3.86,95%CI 1.83-8.12)。
- 治疗IBS-C时腹泻发生率高于安慰剂:利那洛肽290 μg(OR=8.02,95%CI 5.20-12.37);普卡那肽3 mg(OR=5.55,95%CI 1.62-19.00);普卡那肽6 mg(OR=4.13,95%CI 1.57-10.83)。
- 基于Meta回归,两种疗法在疗效、腹泻或腹泻相关研究退组的比值比上无统计学显著差异。
关键数值与推荐
- FDA出版物记录利那洛肽试验与普卡那肽试验使用了不同的腹泻定义。
- 疗效基于FDA批准的复合应答者终点评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Linaclotide and plecanatide are guanylate cyclase-C (GCC) agonists for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Our objective is to evaluate the efficacy and tolerability of GCC agonists based on data from multiple randomized controlled trials (RCTs). METHODS: We searched PubMED, EMBASE, Cochrane databases, clinicaltrials.gov, major conference abstracts, Food and Drug Administration (FDA) websites, and United States Securities and Exchange Commission filings of drug sponsors to identify RCTs of CIC or IBS-C patients. We assessed efficacy based on FDA-approved composite responder endpoints, diarrhea as an adverse event, and study withdrawal owing to diarrhea for each therapy. Trial results were pooled using DerSimonian and Laird random effects model of meta-analysis and exact logistic regression when appropriate with 95% confidence intervals. Meta-regression was performed to compare outcomes between therapies adjusting for placebo event rate. RESULTS: Eight linaclotide trials (five CIC; three IBS-C) and seven plecanatide trials (four CIC; three IBS-C) evaluating 10,369 patients met inclusion criteria. FDA publications documented that different definitions for diarrhea were used in linaclotide vs. plecanatide trials. Both drugs were efficacious in treating CIC (linaclotide 72 μg (Odds ratio (OR)=3.11, 95% CI 1.81-5.34); linaclotide 145 μg (OR=3.25, 2.15-4.91); plecanatide 3 mg (OR=1.99, 1.57-2.51)) and IBS-C (linaclotide 290 μg (OR=2.43, 1.48-3.98); plecanatide 3 mg (OR=1.87, 1.47-2.38); plecanatide 6 mg (OR=1.92, 1.48-2.48)). Diarrhea occurred in excess of placebo in treating CIC (linaclotide 72 μg (OR=3.07, 1.97-4.77); linaclotide 145 μg (OR=3.70, 2.69-5.10); plecanatide 3 mg (OR=3.86, 1.83-8.12)) and IBS-C (linaclotide 290 μg (OR=8.02, 5.20-12.37); plecanatide 3 mg (OR=5.55, 1.62-19.00); plecanatide 6 mg (OR=4.13, 1.57-10.83)). Based on meta-regression, there were no statistically significant differences between therapies in odds ratios for efficacy, diarrhea, or diarrhea-related study withdrawals. CONCLUSIONS: Both linaclotide and plecanatide demonstrate similar efficacy and tolerability in treating IBS-C and CIC. No differences in odds of diarrhea were seen between linaclotide and plecanatide.
引用
- Shah ED, Kim HM, Schoenfeld P, et al. Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2018. PMID: 29380823. doi:10.1038/ajg.2017.495
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。